ZyVersa Therapeutics Inc Financials
This page shows ZyVersa Therapeutics Inc (ZVSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Recent filings show a cash-dependent development model where external financing rather than operating inflows keeps the business moving.
From FY2022 through FY2024, reported losses and operating cash burn stayed aligned: net loss was-$14.0M in FY2022 and-$9.4M in FY2024, while operating cash flow remained negative each year. Because financing inflows added about$13.7M across that span as operations consumed cash, the balance sheet was supplying the fuel rather than accounting adjustments masking a self-funding business.
By FY2025, liquidity had become extremely thin, with cash of
The capital structure also moved from positive equity to a deficit: equity shifted from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of ZyVersa Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
ZyVersa Therapeutics Inc carries a low D/E ratio of -1.04, meaning only $-1.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 73/100, indicating a strong balance sheet with room for future borrowing.
ZyVersa Therapeutics Inc's current ratio of 0.04 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Key Financial Metrics
Earnings & Revenue
ZyVersa Therapeutics Inc earned $-4.18 per diluted share (EPS) in fiscal year 2025. This represents an increase of 50.7% from the prior year.
Cash & Balance Sheet
ZyVersa Therapeutics Inc held $102K in cash against $0 in long-term debt as of fiscal year 2025.
ZyVersa Therapeutics Inc had 8M shares outstanding in fiscal year 2025. This represents an increase of 222.8% from the prior year.
Margins & Returns
Capital Allocation
ZyVersa Therapeutics Inc invested $1.1M in research and development in fiscal year 2025. This represents a decrease of 37.4% from the prior year.
ZVSA Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $58K | N/A | $365K-10.9% | $410K+58.4% | $259K | N/A | $436K-38.5% | $709K |
| SG&A Expenses | $1.2M | N/A | $1.7M+6.4% | $1.6M-13.3% | $1.9M | N/A | $1.8M-10.3% | $2.0M |
| Operating Income | -$1.3M | N/A | N/A | -$2.0M+4.7% | -$2.1M | N/A | -$2.3M+17.6% | -$2.8M |
| Interest Expense | -$133K | N/A | -$131K-1.0% | -$130K-8.8% | -$120K | N/A | -$132K-226856.9% | -$58 |
| Income Tax | N/A | N/A | -$852K | N/A | N/A | N/A | N/A | $10K |
| Net Income | -$1.8M | N/A | N/A | -$2.2M+2.0% | -$2.3M | N/A | -$2.4M+13.1% | -$2.8M |
| EPS (Diluted) | $-0.22 | N/A | $-2.56-456.5% | $-0.46 | $-0.73 | N/A | $-2.43+26.6% | $-3.31 |
ZVSA Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $742K+60.2% | $463K-55.4% | $1.0M-94.7% | $19.6M-6.4% | $21.0M+1.9% | $20.6M+6.1% | $19.4M-0.2% | $19.5M |
| Current Assets | $742K+60.2% | $463K-53.4% | $996K+81.3% | $549K-74.0% | $2.1M+23.0% | $1.7M+339.5% | $390K-39.1% | $641K |
| Cash & Equivalents | $303K+197.4% | $102K-80.7% | $528K+632.4% | $72K-95.5% | $1.6M+5.3% | $1.5M+1145.5% | $123K+2.9% | $119K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $14.9M+15.7% | $12.9M+0.7% | $12.8M-5.7% | $13.5M+5.3% | $12.9M+6.4% | $12.1M-2.5% | $12.4M+14.3% | $10.8M |
| Current Liabilities | $14.9M+15.7% | $12.9M+0.7% | $12.8M+0.6% | $12.7M+5.7% | $12.0M+6.9% | $11.2M-2.7% | $11.5M+15.5% | $10.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$14.1M-14.0% | -$12.4M-5.6% | -$11.7M-292.2% | $6.1M-25.0% | $8.1M-4.5% | $8.5M+21.2% | $7.0M-18.5% | $8.6M |
| Retained Earnings | -$139.4M-1.3% | -$137.6M-0.5% | -$136.9M-16.9% | -$117.1M-1.9% | -$114.9M-2.0% | -$112.6M-1.3% | -$111.2M-2.2% | -$108.8M |
ZVSA Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$799K-93.2% | -$414K+70.6% | -$1.4M+7.5% | -$1.5M+14.1% | -$1.8M-45.9% | -$1.2M-97.8% | -$614K+67.9% | -$1.9M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $1.0M+8093.0% | -$13K-100.7% | $1.9M+10613.6% | -$18K-101.0% | $1.9M-29.4% | $2.6M+324.7% | $618K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ZVSA Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | -36.3%-8.5pp | -27.8% | N/A | -34.2%-2.1pp | -32.1% |
| Return on Assets | -241.6% | N/A | N/A | -11.3%-0.5pp | -10.8% | N/A | -12.4%+1.8pp | -14.2% |
| Current Ratio | 0.05+0.0 | 0.04-0.0 | 0.08+0.0 | 0.04-0.1 | 0.18+0.0 | 0.15+0.1 | 0.03-0.0 | 0.06 |
| Debt-to-Equity | -1.05-0.0 | -1.04+0.1 | -1.09-3.3 | 2.22+0.6 | 1.58+0.2 | 1.42-0.3 | 1.76+0.5 | 1.26 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$12.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What are ZyVersa Therapeutics Inc's total assets?
ZyVersa Therapeutics Inc (ZVSA) had $463K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does ZyVersa Therapeutics Inc spend on research and development?
ZyVersa Therapeutics Inc (ZVSA) invested $1.1M in research and development during fiscal year 2025.
What is ZyVersa Therapeutics Inc's current ratio?
ZyVersa Therapeutics Inc (ZVSA) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is ZyVersa Therapeutics Inc's debt-to-equity ratio?
ZyVersa Therapeutics Inc (ZVSA) had a debt-to-equity ratio of -1.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
Why is ZyVersa Therapeutics Inc's debt-to-equity ratio negative or unusual?
ZyVersa Therapeutics Inc (ZVSA) has negative shareholder equity of -$12.4M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
How financially healthy is ZyVersa Therapeutics Inc?
ZyVersa Therapeutics Inc (ZVSA) scores 12 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.